Literature DB >> 7439242

Effects and pharmacokinetics of isosorbide dinitrate in normal man.

S Spörl-Radun, G Betzien, B Kaufmann, V Liede, U Abshagen.   

Abstract

18 subjects were given isosorbide dinitrate (ISDN) 5 mg sublingually and serum concentrations of ISDN, 2-isosorbide mononitrate (2-ISMN) and 5-isosorbide mononitrate (5-ISMN) were measured, as well as changes in digital plethysmographic amplitude, heart rate, ECG, blood pressure and Schellong's test. ISDN was rapidly absorbed and metabolized, having an elimination half-life of 29 min. Its metabolites 2-ISMN and 5-ISMN had longer half-lives of 1.75 and 7.6 h respectively. The amplitude of the alpha-wave of the digital plethysmograph did not change significantly either in the pre-drug period or after placebo administration. It increased within 4 min of administration of ISDN, and reached a maximum after 14 min; the effect lasted for about 2 h. ISDN lowers blood pressure and increases heart rate in most volunteers, but in 3 of the 18 subjects severe hypotension occurred, accompanied by severe, reversible bradycardia, which was probably due to vagal reflexes initiated by the markedly diminished ventricular enddiastolic volume (LVEDV) and pressure (LVEDP). No correlation could be demonstrated between the serum concentration of ISDN and/or its vasoactive metabolites and changes in plethysmographic amplitude.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439242     DOI: 10.1007/bf00563005

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure.

Authors:  R Gray; K Chatterjee; J K Vyden; W Ganz; J S Forrester; H J Swan
Journal:  Am Heart J       Date:  1975-09       Impact factor: 4.749

2.  Quantitative determination of isosorbide dinitrate and two metabolites in plasma.

Authors:  D A Chin; D G Prue; J Michelucci; B T Kho; C R Warner
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

3.  [Unfavourable effects of the sublingual isosorbide dinitrate. Osbervations on nine personal cases (author's transl)].

Authors:  A Lax; V Ceci; G Jacovella
Journal:  G Ital Cardiol       Date:  1977-08

Review 4.  Recent views on the mechanisms of nitrate ester metabolism.

Authors:  M H Litchfield
Journal:  Drug Metab Rev       Date:  1973       Impact factor: 4.518

5.  Mechanism of tolerance development to organic nitrates.

Authors:  P Needleman; E M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

6.  New dimension in angina pectoris therapy.

Authors:  H I Russek
Journal:  Geriatrics       Date:  1969-03

Review 7.  Isosorbide dinitrate for the relief of severe heart failure after myocardial infarction.

Authors:  J A Mantle; R O Russell; R E Moraski; C E Rackley
Journal:  Am J Cardiol       Date:  1976-02       Impact factor: 2.778

8.  The mechanism of orthostatic and haemorrhage fainting.

Authors:  L Bergenwald; U Freyschuss; T Sjöstrand
Journal:  Scand J Clin Lab Invest       Date:  1977-05       Impact factor: 1.713

9.  [Sublingual isosorbide dinitrate-induced severe hypotension, bradycardia and prelypothymia in patients with acute myocardial infarction (author's transl)].

Authors:  M Bossi; G Cataldo; A Colombo; F Fiorista; D Gentili; S Pirelli
Journal:  G Ital Cardiol       Date:  1977

10.  Improved method for the rapid determination of isosorbide dinitrate in human plasma and its application in pharmacokinetic studies.

Authors:  H Laufen; F Scharpf; G Bartsch
Journal:  J Chromatogr       Date:  1978-11-01
View more
  14 in total

Review 1.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

3.  Intra-individual comparison of the action of equal doses of isosorbide-5-endomononitrate, slow-release isosorbide dinitrate and placebo in patients with coronary heart disease.

Authors:  G Müller; W Häcker; B Schneider
Journal:  Klin Wochenschr       Date:  1983-04-15

4.  Experience of long term treatment and different dosage regimens of isosorbide 5-mononitrate.

Authors:  M Meffert; I M Paeckelmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man.

Authors:  U Abshagen; S Spörl-Radun
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Bronchodilator effect of sublingual isosorbide dinitrate in asthma.

Authors:  M Okayama; H Sasaki; T Takishima
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of organic nitrates.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

8.  Fate of isosorbide dinitrate and mononitrates in patients with renal failure.

Authors:  M G Bogaert; M T Rosseel; J Boelaert; R Daneels
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.

Authors:  U Abshagen; G Betzien; R Endele; B Kaufmann; G Neugebauer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Isosorbide-5-mononitrate in the treatment of acute left ventricular failure following acute myocardial infarction.

Authors:  M D Gammage; R G Murray; W A Littler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.